TY - JOUR
T1 - Immunohistochemistry – Microarray Analysis of Patients with Peritoneal Metastases of Appendiceal or Colorectal Origin
AU - Green, Danielle E.
AU - Jayakrishnan, Thejus T.
AU - Hwang, Michael
AU - Pappas, Sam G.
AU - Gamblin, T. Clark
AU - Turaga, Kiran K.
N1 - Funding Information:
We would like to acknowledge the role of Dr. Joanne Xiu, PhD from CARIS Life Sciences who assisted with review of the methods of the study to verify accuracy of the technique. Role of Funding Source: This study was supported by the Sebastian Raclaw Abdominal Cancer Fund. The study sponsor had no involvement in the study.
Publisher Copyright:
© Copyright © 2015 Green, Jayakrishnan, Hwang, Pappas, Gamblin and Turaga.
PY - 2015/1/5
Y1 - 2015/1/5
N2 - Background: The value of immunohistochemistry (IHC)-microarray analysis of pathological specimens in the management of patients is controversial, although preliminary data suggest potential benefit. We describe the characteristics of patients undergoing a commercially available IHC-microarray method in patients with peritoneal metastases (PM) and the feasibility of this technique in this population. Methods: We retrospectively analyzed consecutive patients with pathologically confirmed PM from appendiceal or colorectal primary who underwent Caris Molecular Intelligence™ testing. IHC, microarray, FISH, and mutational analysis were included and stratified by Peritoneal Carcinomatosis Index (PCI) score, histology, and treatment characteristics. Statistical analysis was performed using non-parametric tests. Results: Our study included 5 patients with appendiceal and 11 with colorectal PM. The median age of patients was 51 (IQR 39–65) years, with 11 (68%) female. The median PCI score of the patients was 17 (IQR 10–25). Hyperthermic intra-peritoneal chemoperfusion was performed in 4 (80%) patients with appendiceal primary tumors and 4 (36%) with colorectal primary. KRAS mutations were encountered in 40% of appendiceal vs. 30% colorectal tumors, while BRAF mutations were seen in 40% of colorectal PM and none of the patients with appendiceal PM (p = 0.06). IHC biomarker expression was not significantly different between the two primaries. Sufficient tumor for microarray analysis was found in 44% (n = 7) patients, which was not associated with previous use of chemotherapy (p > 0.20 for 5-FU/LV, Irinotecan and Oxaliplatin). Conclusion: In a small sample of patients with PM, the feasibility and results of IHC-microarray staining based on a commercially available test is reported. The apparent high incidence of the BRAF mutation in patients with PM may potentially offer opportunities for novel therapeutics and suggest that IHC-microarray is a method that can be used in this population.
AB - Background: The value of immunohistochemistry (IHC)-microarray analysis of pathological specimens in the management of patients is controversial, although preliminary data suggest potential benefit. We describe the characteristics of patients undergoing a commercially available IHC-microarray method in patients with peritoneal metastases (PM) and the feasibility of this technique in this population. Methods: We retrospectively analyzed consecutive patients with pathologically confirmed PM from appendiceal or colorectal primary who underwent Caris Molecular Intelligence™ testing. IHC, microarray, FISH, and mutational analysis were included and stratified by Peritoneal Carcinomatosis Index (PCI) score, histology, and treatment characteristics. Statistical analysis was performed using non-parametric tests. Results: Our study included 5 patients with appendiceal and 11 with colorectal PM. The median age of patients was 51 (IQR 39–65) years, with 11 (68%) female. The median PCI score of the patients was 17 (IQR 10–25). Hyperthermic intra-peritoneal chemoperfusion was performed in 4 (80%) patients with appendiceal primary tumors and 4 (36%) with colorectal primary. KRAS mutations were encountered in 40% of appendiceal vs. 30% colorectal tumors, while BRAF mutations were seen in 40% of colorectal PM and none of the patients with appendiceal PM (p = 0.06). IHC biomarker expression was not significantly different between the two primaries. Sufficient tumor for microarray analysis was found in 44% (n = 7) patients, which was not associated with previous use of chemotherapy (p > 0.20 for 5-FU/LV, Irinotecan and Oxaliplatin). Conclusion: In a small sample of patients with PM, the feasibility and results of IHC-microarray staining based on a commercially available test is reported. The apparent high incidence of the BRAF mutation in patients with PM may potentially offer opportunities for novel therapeutics and suggest that IHC-microarray is a method that can be used in this population.
KW - DNA mutational analysis
KW - appendiceal neoplasms
KW - colorectal neoplasms
KW - immunohistochemistry
KW - microarray analysis
KW - peritoneal neoplasms
UR - http://www.scopus.com/inward/record.url?scp=84971628732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971628732&partnerID=8YFLogxK
U2 - 10.3389/fsurg.2014.00050
DO - 10.3389/fsurg.2014.00050
M3 - Article
C2 - 25593974
AN - SCOPUS:84971628732
SN - 2296-875X
VL - 1
JO - Frontiers in Surgery
JF - Frontiers in Surgery
M1 - 50
ER -